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Background: Osteosarcoma (OS) is the most common primary bone malignancy with a high propensity for local
invasion and distant metastasis. Limited by the severe toxicity of conventional agents, the therapeutic bottleneck of
osteosarcoma still remains unconquered. Flavokawain B (FKB), a kava extract, has been reported to have significant
anti-tumor effects on several carcinoma cell lines both in vitro and in vivo. Its efficacy and low toxicity profile make
FKB a promising agent for use as a novel chemotherapeutic agent.
Results: In the current study, we investigated the anti-proliferative and apoptotic effects of FKB against human
osteosarcomas. Exposure of OS cells to FKB resulted in apoptosis, evidenced by loss of cell viability, morphological
changes and the externalization of phosphatidylserine. Apoptosis induced by FKB resulted in activation of
Caspase-3/7, -8 and −9 in OS cell lines, 143B and Saos-2. FKB also down-regulated inhibitory apoptotic markers,
including Bcl-2 and Survivin and led to concomitant increases in apoptotic proteins, Bax, Puma and Fas. Therefore,
the induction of apoptosis by FKB involved both extrinsic and intrinsic pathways. FKB also caused G2/M phase cell
cycle arrest, which was observed through reductions in the levels of cyclin B1, cdc2 and cdc25c and increases in
Myt1 levels. Furthermore, migration and invasion ability was decreased by FKB in a dose-dependent manner. The
cytotoxicity profile showed FKB had significant lower side effects on bone marrow cells and small intestinal epithelial
cells compared with Adriamycin.
Conclusions: Taken together, our evidence of apoptosis and cell cycle arrest by FKB treatment with less toxicity than
the standard treatments provides an innovative argument for the use of FKB as a chemotherapeutic and
chemopreventive compound. In vivo experiments utilizing FKB to reduce tumorigenesis and metastatic potential will
be crucial to further justify clinical application.
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Osteosarcoma is the most common primary malignant
tumor arising from bone in children and young adults
with a very high propensity for local invasion and distant
metastasis. Despite new therapeutic developments the
survival data for this disease remains unchanged over
the past 20 years [1]. Conventional chemotherapy proto-
cols contain a similar three-drug backbone consisting of
methotrexate, doxorubicin, and cisplatin (MAP) with the* Correspondence: bhhoang@uci.edu
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reproduction in any medium, provided the orpossible inclusion of ifosfamide and etoposide [2]. Given
that the current chemotherapy regimens have had limited
success in improving metastasis-free survival and the poor
response of previously treated patients with relapsed osteo-
sarcoma, we investigated the potential application of nat-
ural anticancer agents in treatment of osteosarcoma.
Natural products have played a major role in new drug
discovery for centuries, with over 47% of approved antican-
cer agents being of natural origin [3]. These compounds
can be used as antioxidants and cancer preventing agents
or cancer therapy drugs. The consumption of kava root ex-
tracts in the Pacific Islands has been associated with a
lower incidence of cancer [4]. Extracts of kava are classified
into two main classes of compounds: kavalactone andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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via inhibition of cell proliferation, carcinogenesis and me-
tastasis [4,7,8]. The chalcones include Flavokawain A, B
and C. Recent studies have shown that flavokawains are
apoptotic inducers and anticarcinogenic agents. We, and
others, recently demonstrated that flavokawavin B (FKB)
induced apoptosis and exhibited both in vitro and in vivo
anticancer activity against bladder, prostate, colon, oral,
lung cancer cells, and also mesenchymal tumors including
synovial sarcoma and uterine leiomyosarcoma [5,9-14].
These findings encouraged us to investigate the anticancer
effects of FKB on OS as a novel compound agent.
Results
FKB inhibits proliferation of osteosarcoma cells
To investigate the effects of FKB on growth, 143B,
OS160, MG-63 and Saos-2 cells were exposed to 6 dif-
ferent concentrations for 72 h. Fibroblast cells were used
as a control. Figure 1A shows that FKB induced cell
death in a dose-dependent manner. FKB at a dose of
5 μg/ml can inhibit the growth of 143B cells by about
90%. The inhibitory effect was also observed in other
three osteosarcoma cell lines. The half-inhibitory con-
centration (IC50) of FKB for 72 h on 143B cells was ap-
proximately 1.97 μg/ml (3.5 μM). Figure 1B shows that
the treatment of 143B cells with FKB resulted in a sig-
nificant inhibition of cell growth in a time-dependent
manner. The 72 h inhibition was more significant than
that of 24 h (p<0.05).
The soft agar colony formation assay showed 143B
cells formed significantly fewer colonies after FKB treat-
ment (p<0.01, Figure 1C) The results further suggest
that treatment of 143B cells with FKB produces result in
a significant inhibition of growth in a dose-dependent
manner.
Induction of apoptosis in both 143B and saos-2 cell lines
by FKB
To determine whether the inhibition of cell growth by
FKB resulted from the induction of apoptosis, morph-
ology study, DAPI staining and FACS were used. The
two cell lines exhibited typical apoptotic morphologic
changes, including chromatin condensation, separation
from surrounding cell, cell shrinkage and cell rounding
(data not shown). Following treatment with FKB 24 h,
control cells showed round and homogeneous nuclei,
whereas cells treated with FKB displayed condensed and
fragmented nuclei (Figure 2A). FACS analysis showed
that FKB treatment resulted in an increase in both early
(lower right) and late apoptotic cells along with the nec-
rotic fractions (upper right) in both 143B and Saos-2 cell
lines (Figure 2B and C). The percentage of apoptotic
Saos-2 and 143B cells was 45.1±6.4% and 22.7±2.8%, re-
spectively after FKB treatment at the dose of 7.5 μg/ml.FKB up-regulates expression of pro-apoptoic protein and
down-regulates anti-apototic protein
Apoptosis can be induced via the extrinsic pathway,
through cell surface death receptor stimulation, or through
the intrinsic pathway mediated by mitochondrial dysfunc-
tion [15]. Figure 2D illustrates that FKB treatment of 143B
and Saos-2 resulted in increased expression of Fas, Puma
and Bax, while down-regulating the expression of Bcl-2
and Survivin. Also, FKB treatment increases Caspase 8, 9,
3/7 activity compared to vehicle-treated controls with a
dose-dependent manner (Additional file 1). Taken together,
these results imply that FKB activates both extrinsic and
intrinsic apoptotic pathways, exhibiting apoptotic effects
against osteosarcoma cells.
FKB suppressed in vitro motility and invasiveness
To examine whether FKB affect the motility and in-
vasiveness of osteosarcoma cells, we have performed
scratch assays. The wound healing area of 143B cells
after FKB treatment for 16h was lower than that of control
(96.3± 1.8)% with a dose-dependent manner. The migra-
tion rate was significantly decreased when the cells were
exposed to FKB at the dose of 5.0 μg/ml and 7.5 μg/ml
with healed percent of 49.1±9.4 (p=0.01) and 30.1±8.2
(p<0.01), respectively (Figure 3A).
The Matrigel transwell assay showed there was nega-
tive correlation between the FKB concentration and the
number of osteosarcoma cells that had invaded/migrated
through Matrigel. FKB significantly inhibited both 143B
and Saos-2 cells invasion in a dose-dependent manner,
with 54.6% and 62.7%, respectively (both p=0.01) com-
pared to control at 2.5 μg/ml, 5.5% and 35.4% (p<0.001)
at 5.0 μg/ml, and 0% and 0.5% (p<0.001) at 7.5 μg/ml, as
shown in Figure 3B.
Effects of FKB on MMP-2 and MMP-9
Zymography demonstrated MMP-2 and MMP-9 secretion
by normal and FKB-treated 143B cells. FKB inhibited
the secretion of both MMPs in a dose-dependent man-
ner with almost total inhibition of MMP-9 and MMP-2
at 7.5 μg/ml, as shown in Figure 3C. MMP-2 and MMP-9
secretion level of untreated cells was inhibited by 38.9%
and 59.5%, respectively at 5.0 μg/ml FKB and by 91% at
7.5 μg/ml FKB (linear trend, both R2=0.93) (Figure 3C).
Western blotting showed that FKB reduced the protein
levels of MMP-2 and MMP-9.
FKB induces G2/M arrest in 143B and saos-2 cells
To examine whether FKB treatment could affect cell
cycle progression in osteosarcoma cells, asynchronous
143B and Saos-2 cells were treated with different con-
centrations of FKB. As shown in Figure 4A, FKB treat-
ment results in a marked increase in the number of cells
arrested at G2/M phase in both 143B and Saos-2 cell
Figure 1 Antiproliferative effect of FKB on OS cells. A, Four OS cell lines and fibroblast cell line (HESC) were used and cells were treated with
FKB at the indicated concentration in the figure for 72 h, and cell viabilities were measured by MTT assay. B, 143B cells were treated with indicated
concentrations for 24, 48 or 72 h. C, anchorage-independent colony formation assay showed significantly decreased number of colonies formed by
143B cells treated with FKB compared with control group; inset, representative photography of soft agar colonies at 14 days after cell seeding. An
asterisk (*) indicates a significant difference in comparison with the control group (p<0.05).
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Figure 2 The apoptotic effect of FKB on OS cells. A, 143B cells were treated with different concentrations of FKB for 24 h. Apoptosis was
evaluated by DAPI staining. B, 143B and Saos-2 cells were stained with annexin V and propidium iodide and analyzed by flow-cytometry. C, The
chart illustrates the results from three separate experiments of flow-cytomety. D, FKB treatment induced the expression of Fas, Bax, Puma, and
decreased Survivin and Bcl-2 expression. Cells were treated for 24 h and protein was resolved by SDS-PAGE with GAPDH as a control.
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effects of FKB on cell cycle progression we synchronized
143B cells in mitosis phase using nocodazole and subse-
quently released the cell into FKB 5.0 μg/ml or vehicle
control containing media. Analysis of collected cells by
flow cytomoetry indicated that control cells progressed
normally through mitosis and by 16 hours had lost their
synchrony (Figure 4B). In contrast, cells released into FKB
(5.0 μg/ml) stayed in M-phase over the time course tested.The cell cycle profile observed was consistent with that
previously detected on asynchronous cell lines.
Effects of FKB on expression of cell-cycle regulator markers
Cell cycle progression is regulated by the cycling ac-
tions of the cyclin-CDK complexes and positive and
negative regulator proteins [16,17]. Regulation of the cyclin
dependent kinase Cdc2 is essential for entry into mitosis.
During G2, the Cdc2/Cyclin B complex is kept inactive by
Figure 3 FKB suppressed cell motility and invasiveness. A, Representative photomicrographs of scratch wounds were taken at 0 and 16 h
after wound were made on 143B treated with FKB 7.5 μg/ml or control. Quantitative measurement of wound healed by ImageJ software showed
a reduced cellular motility in FKB-treated 143B cells compared with control group. Columns, mean relative area (%) of wound healed; bars, SD.
Experiments were replicated thrice. B, Cell invasion ability was analyzed by the Transwell chamber 36 h after FKB treatment at indicated
concentration. The number of migrated cells was significantly decreased by FKB in a dose-dependent manner. C, Zymography and western
blotting analysis of MMP-2 and MMP-9 from cultured medium of 143B cells treated with FKB. Both MMP-2 and MMP-9 activities were significant
inhibited by FKB. Also the same inhibition effect of FKB on MMPs was observed on protein expression levels.
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At the onset of mitosis, both of these residues are
dephosphorylated by the phosphatase Cdc25C. Therefore,
we hypothesized that the FKB induced G2/M arrest may
be caused by inhibition of Cyclin B1, Cdc25C and acti-
vation of Wee1 and Myt1. As expected, FKB treatmentat 5.0 μg/ml caused significant decrease in Cyclin B1, Cdc
25c and increase in p-Cdc2 in a time-dependent manner
(Figure 4C). However, Myt1 showed an increase but
not time dependent. No significant increase was found
for Wee1 expression. These results imply that FKB inhibit
cell cycle progression, at least partially, by decreasing the
Figure 4 FKB induced G2/M arrest in OS cells. A, 143B and Saos-2 cells were treated with vehicle control or FKB at different
concentrations for 24 h and analyzed for cell cycle. Percentage of cell cycle distribution after FKB treatment was presented. Points, mean
of three samples for each concentration; bars, SE. B, 143B cells were blocked at G2/M phase and released form the block into either
control or 5 μg/ml FKB. At times indicated, cells were collected, fixed, and analyzed by flow cytometry. C, The effect of FKB (5 μg/ml) on
cell-cycle regulatory markers was examined by Western blot analysis. The protein extracted from 143B cells treated with FKB for indicated
time was resolved by SDS-PAGE.
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143B cells.
In vitro toxicity assay of FKB
No significant growth inhibitory effects were observed in
the growth of bone marrow cells. Significant differences in
cell viability was noted between normal small intestinalepithelial cells and osteosarcoma cells following FKB treat-
ment (p=0.016) (Figure 5A). Bone marrow cell colony for-
mation showed there was no difference in the number of
colonies after FKB treatment, however the typical size of
colonies decreased in a dose dependent manner (Figure 5B
and C). Significant growth inhibition was noted with
Adriamycin treatment at all concentrations.
Figure 5 FKB showed preferential inhibition on 143B cells
compared with FHS and bone marrow stem cells. A, FKB
treatment exhibited differential effects on 143B OS cells, normal small
intestinal epithelial cell (FHS) and bone marrow stem cells. Cells were
treated with FKB for 72 h. B, Compared with Adriamycin, FKB showed
significantly less bone marrow inhibition effect. C, Representative
microphotography, taken at 14 days after treatment of bone marrow
stem cell colonies showed the size of a typical colony decreased with
a higher concentration of FKB.
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In spite of aggressive treatment protocols including
high-dose chemotherapy and wide surgical resection,
the long-term survival of patients with localized disease
remains between 60-70% during the last two decades
[18]. Although maximal dose escalation of conventional
chemotherapy has been utilized, there is still no signifi-
cant gain in clinical outcome. The use of conventional
antitumor drugs, such as doxorubicin and methotrexate,
is usually limited due to their systemic toxicity and lack
of specificity [19]. Furthermore, no effective standard
second-line chemotherapeutic agent has been identifiedin local or distant relapsed osteosarcoma. Many reports
have emphasized that use of dietary bioactive compounds
is becoming an alternative, safe, and desirable approach to
controlling and treating cancer [20]. Our previous studies
have shown that FKB exhibits cytotoxic potency against
mesenchymal tumors, including synovial sarcoma and
uterine leiomyosarcoma [9,12]. The results presented here
confirm that FKB could inhibits proliferation of human
osteosarcoma cells in vitro via G2/M arrest and leads to a
robust induction of apoptosis.
We further evaluated the regulatory mechanism for
the apoptotic effect of FKB in osteosarcoma cells. Inves-
tigations have shown that apoptosis is controlled by both
mitochondrial and membrane death receptor pathways.
Previous reported research showed that the mechanisms
through which FKB induces apoptosis depend primarily on
mitochondrial damage [8,20]. The pro-survival protein
Bcl-2, combined with Bax, can regulate apoptosis via hom-
ologous and heterogeneous complexes. Bax induces the
release of cytochrome c and activates the Bax-initiated
mitochondria pathway and the capsese 3-dependent apop-
totic pathway. Bcl-2 inhibits the realease of cytochrome c
against Bax. The disturbance of Bcl-2/Bax protein ratio has
been recognized as a factor contributing to the FKB-
induced apoptosis [6,20]. In the present study, the increase
in Bax and decrease in Bcl-2 was observed in both OS
cell lines. Also activity level of caspase-3 was found to
increase incrementally with escalating doses. The extrin-
sic pathway is initiated by the binding of transmembrane
death receptors, including Fas, DR5 and TNFR receptors
[15]. Activation of Fas receptor leads to receptor cluster-
ing and formation of a death-inducing signaling complex,
which results in the activation of procapase-8. Then
active caspase-8 can then go on trigger the apoptotic
caspase cascade. Fas expression may be triggered by FKB
treatment and may account for independent activation of
caspase-9. Puma is a critical mediator of p53-dependent
and p53-independent apoptosis induced by a wide variety
of stimuli, including deregulated oncogene expression,
toxins, growth factor/cytokine withdrawal, and infection
[21]. It has been suggested that Puma can also sponsor
apoptosis by directly activating Bax in some cells [22]. Data
from the present study suggests that FKB-induced apop-
tosis is mediated by both mitochondrial and membrane
death receptor pathways.
Many conventional anticancer treatments at least partly
damage the DNA of cells without specific selectivity select-
ive for cancer cells. Anticancer insights derived from cell
cycle research has given birth to the idea of cell cycle G2
checkpoint abrogation as a cancer specific therapy [23].
Several studies have revealed that FKB induce G2/M arrest
[12,20,24]. In current study, significant G2/M arrest
by FKB in osteosarcoma cells was confirmed by synchro-
nized cell cycle analysis. Further mechanism was explored.
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in Cyclin B1 and Cdc25C and increase in Myt1, and
phosphorylation-cdc2. During G2, the Cdc2/Cyclin B
complex is kept inactive by phosphorylation by the
kinase Myt1 [25]. At the onset of mitosis, both residues are
dephosphorylated by Cdc25C [26]. Repression of Cyclin B1
and Cdc2 enforces the G2/M arrest. Inhibitory phosphoryl-
ation of Cdc2 is essential for the p53-independent G2 ar-
rest that occurs in response to DNA damage, and is
dependent on the protein kinases Atm and Atr. The Cdc2
is inactivated by Atm and Atr through increasing phos-
phorylation of the residues tyrosine 15, which cause G2 ar-
rest in response to DNA damage [17]. We found that FKB
did not change the expression level of p53 (Data not
shown). Hence, p53-independent G2 arrest may be the
main mechanism in FKB-induced cell cycle block.
Results of motility and invasion assays encouraged
the potential use of FKB as a new candidate for anti-
cancer therapy against migration and invasion of osteo-
sarcoma cells. Inhibition of motility and invasion with
dose-dependent manner was observed in 143B and
Saos-2 cell lines. To further explore the exact expression of
FKB-induced inhibition of invasion and migration, we
performed a gelatin zymography assay to detect the activ-
ities of MMP-2 and MMP-9 in 143B cells. The results
showed that FKB notably down-regulated activities and
protein levels of MMP-2 and MMP-9 in a dose-dependent
manner. One of the major characteristics of cancer cell
metastasis is altered adhesion ability between cells and the
extracellular matrix which is associated with invasion and
migration of tumor cells [27]. MMPs are overexpressed in
the metastatic tumor cells and have been shown to be in-
volved in the invasion and metastasis of various tumor
cells [28]. High MMP-9 expression was observed in pre-
treatment osteosarcoma tumor samples and in most meta-
static lesions, leading to the speculation that MMP-9 is
associated with the micrometastatic behavior of osteosar-
coma [29]. It is well-established that inhibitions of MMP
enzyme activity are early targets for preventing cancer me-
tastasis [30]. Both MMP-2 and MMP-9 are involved with
the invasive metastatic potential of tumor cells. The
current resutls clearly showed that FKB inhibited the mi-
gration and invasion of 143B and Saos-2 cells in vitro,
which may account for its inhibitory effect on tumor me-
tastasis. Here we found the protein activity of MMP-2 and
MMP-9 [28], which are involved in degradation of extra-
cellular matrix and play vital roles in cancer cell migration
and invasion.
Any discussion surrounding novel therapeutics must in-
clude concerns regarding untoward side effects. The tox-
icity is an important feature to be considered when a
compound is used for treatment, especially for chemopre-
ventive purposes. In order to investigate the potential toxic
effect on the resident normal bone marrow mesenchysmalstem cells, we used murine bone marrow cells to study
possible toxicity. Notably, the bone marrow cells were
quite significantly less sensitive to the FKB, thereby
suggesting a preferential toxicity on tumor cells. Com-
pared with adriamycin, FKB showed a considerably lower
toxicity on bone marrow cells in the colony formation
assay (Figure 5C). FKB was found to have potent hepato-
cellular toxin [31]. However, the LD50 for the two normal
liver cell lines was 5- and 10-fold greater than the IC50
identified in the current experiment for osteosarcoma
cell lines. Based on the in vitro results, FKB showed che-
motherapeutic effect on tumor cells with significant less
toxic effect on normal cells, suggesting its potential use
in chemoprevention of OS. Nonetheless, characterization
of in vivo toxicities related to FKB is highly warranted.
Conclusion
FKB, a novel chalcone isolated from kava root extracts,
showed a strong in vitro activity against osteosarcoma
cell lines. This compound inhibited cell proliferation, in-
duced apoptosis and cell cycle arrest. Furthermore, the
treatment with FKB, in contrast to conventional chemo-
therapeutic drugs, showed less toxicity in normal bone
marrow cells. This implies that FKB may be used as a
chemopreventive agent with respect to inhibition of tumor
growth, motility and invasion. These preliminary data of
FKB treatment on osteosarcoma cells suggest it may en-
hance the treatment of osteosarcoma.
Methods
Cell lines, compounds, and reagents
OS160 was a gift from Dr. Richard Gorlick (Albert Einstein
College of Medicine, Bronx, NY). Human OS cell lines
143B , SaOS-2, MG-63 and U2OS were maintained in
MEMα medium supplemented with 10% fetal bovine
serum. Human small intestinal cell line FHS (American
Type Culture Collection, ATCC) were maintained and
Hybri-Care Medium. All cells were cultured at 37°C in
a humidified incubator with 5% CO2. Pure FKB was
purchased from LKT laboratories, dissolved in dimethyl
sulfoxide (DMSO), aliquoted, and stored at −20°C. Pri-
mary antibodies for Survivin, Bax, Bcl-2, Bcl-xl, Fas,
cdc25c, Myt1, cdc2, P-cdc2, Wee1, CyclinB1, P-Chk1(345),
GAPDH and secondary antibodies were purchased from
Cell Signaling Technology, and antibodies against MMP-2
and MMP-9 were obtained from Thermo Scientific.
Thymidine,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetraz-
olium bromide (MTT) was obtained from Sigma.
MTT assay
Briefly, cells were plated into 24-well plates at a density of
2×104 cells in 500 μl of growth medium 24 h prior to treat-
ment. Following treatment with FKB at different doses for
72 h, 500 μL of MTT solution was added to each well and
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was then extracted and 500 μL of dissolving buffer was
added to each well. Cell viability was assessed by measuring
absorbance at 570 nm in a microplate reader (Bio-Rad).
Dose response curves were then created as a percentage of
vehicle treated control cells using Excel software.
Soft agar colony formation assay
Soft agar colony formation assays were done using 6-well
plate. Each well contained 2 ml of 0.8% agar in complete
medium as the bottom layer, 1 ml of 0.35% agar in
complete medium, 6,000 cells as the feeder layer, and
1 ml complete medium as the top layer. Each well was
treated with FKB at varying concentrations. Cultures were
maintained under standard culture conditions. The num-
ber of colonies was determined with an inverted phase-
contrast microscope at ×40 magnification. A group of >10
cells was counted as a colony. The data is shown as mean
number of colonies±SEM of four independent wells at
14 days after the start of cell seeding.
DAPI staining for apoptotic cell nuclei
Apoptotic nuclear changes were assessed by ready-to
-use DAPI kit (NucBlue™ Fixed Cell Stain, Invitrogen).
The cells were seeded into 6-well plates. After treatment
with different concentrations of FKB for 24 h, the cells
were fixed with Image-IT™ Fix-Perm kit (Invitrogen) as
detailed in the package insert. Fluorescence microscopy
(Nikon, TE2000-S) was used to observe the apoptotic
characteristics of nuclear condensation.
Caspase activity assay
Apoptosis was confirmed using the Caspase-Glo® 3/7,
Caspase-Glo® 8, and Caspase-Glo® 9 Assay (Promega)
according to the manufacturer’s instructions. Cells were
plated in a 96-well plate and treated with 0.1% DMSO or
FKB for 24 h. Then 100 μl reagent were added to each well
and the luminescence of each sample was measured in a
luminometer (GloMaxVR-MultiDetection System).
Fluorescence-activated cell sorting (FACS) analysis
FACS analysis of apoptosis was performed utilizing
the Annexin V-FITC Apoptosis Detection Kit I (BD
Pharmingen) as previously reported [12]. Briefly, 2×105
143B and Saos-2 cells were seeded into 60-mm dishes
24 h before treatment. Cells were then treated with
0.1% DMSO or different concentrations of FKB for 24
h. Following treatment, the cells were washed with
cold phosphate buffered saline (PBS) × 2, and stained
with FITC annexin-V/propidium iodide (PI) solution
at room temperature, in the dark, for 15 min. Treated
samples were then analyzed immediately in a FACSAria
flow cytometer (BD Biosciences). The percentage of cells
undergoing apoptosis was determined using Multicycle(Phoenix, USA). Annexin-V-FITC(−)/PI(−) was used to in-
dicate cells that had survived, Annexin-V-FITC(+)/PI(−)
was used to indicate cells that were in the early stage of
apoptosis, and Annexin-V-FITC(+)/PI(+) was used to indi-
cate cells in the late stages of apoptosis or necrosis.
FACS analysis of cell cycle
Once 143B cells achieved a 70% to 80% confluency, they
were treated with 0.1% DMSO or different concentration
of FKB for 24 h, or treated with FKB at 5 μg/ml for 2, 4,
6, 8, 10, 12, 16 and 24 h. For synchronization experiment,
143B cells were treated with 100 ng/mL of nocodazole
(Sigma) for 24 h at 37°C prior to being released into 0.1%
DMSO or FKB at 5 μg/ml. After treatment, cells were fixed
in ice-cold 70% ethanol overnight. After fixation, cells were
washed thrice with cold PBS and then stained in 500 μl of
propidium iodide solution. Samples were analyzed on a BD
FACScan flow cytometer and the percentage of cells in
the S, G0-G1, and G2-M phases of the cell cycle was
determined using WinMDI 2.8.
Protein isolation and western blot analysis
Samples (normalized according to cell number) were
treated with FKB at varying concentrations over 24 h or
treated with FKB at 5 μg/μl over different time points. Cell
extracts were then prepared in RIPA lysis buffer containing
protease inhibitors (Sigma). Cell lysates were centrifuged at
13,000 g for 30 min and the supernatant was collected.
The BCA assay was used to determine protein concentra-
tion. Volumes of clarified protein lysate containing equal
amounts of protein (50 μg) were then separated on 8-12%
sodium deodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and electrophoretically (90 min at 100 V)
transferred to a Hybond-ECL membrane (GE Healthcare).
Blots were then blocked for 1 h in TBST containing
5% blocking grade non-fat dry milk (Bio-Rad), and
then incubated overnight with primary antibody at 4°C.
Blots were then washed three times in TBST and incubated
for 1.5 h at room temperature with HRP-conjugated sec-
ondary antibody. Immunoreactive bands were visualized
using an enhanced chemiluminescence detection system
(Thermo Scientific).
Zymogram assay
To determine proenzyme and active form of MMP-2 and
MMP-9, zymogram assay was performed as previously
described [32]. In brief, the FBS-free medium was col-
lected from 143B cells treated with FKB or 0.1% DMSO
for 72 h, and concentrated using Centricon® Plus-70, 30K
NMWL (Millipore). Then the medium with same amount
of protein (30 μg) was separated by electrophoresis in
0.1% gelatin-impregnated gel (Bio-Rad). After being
re-natured at room temperature for one hour in zymogram
re-nature buffer, the gel was incubated overnight at 37°C
Ji et al. Molecular Cancer 2013, 12:55 Page 10 of 11
http://www.molecular-cancer.com/content/12/1/55in zymogram development buffer (Bio-Rad). Gel was
then stained with SimplyBlue SafeStain (Invitrogen) and
destained according to the manufacturer’s protocols
(Bio-Rad). Gelatinolytic activity was visualized as clear
bands on the gel. The gel was then scanned and relative
changes in bands were measured by densitometry using
ImageJ software.
Motility and invasion assay
Motility was assessed with a scratch assay [33]. Cells were
seeded in a 6-well plate at a density of 1×106 cells/well in
growth medium until they reached a confluence of 90% ap-
proximately. A scratch was made through each well using
a sterile pipette tip. The monolayer was incubated with a
migration assay buffer consisting of serum-free medium
and different concentration of FKB. Images were captured
at the same position at 0 h and 16 h. The area of wound
healed was calculated with ImageJ software [34]. Invasion
assay were performed using 24-well invasion chamber sys-
tem (BD Biosciences). The matrigel coated inserts were
used for invasion assay. 1×105 cells were seeded in the
upper chamber in serum-free MEMα medium. MEMα
medium with 10% FBS was placed in the bottom well.
Incubation was carried out for 36 h at 37°C in humidified
air with 5% CO2. Non-invaded cells in the upper chamber
were then removed with a cotton swab. Invaded cells be-
neath the bottom membrane of the inserts were fixed with
methanol and stained with hematoxylin. The number of
invading or migrating cells was determined by counting
five fields (100×) under the microscope, and calculated as
mean number of cells per field. All the research was
performed in triplicate.
In vitro cytotoxicity assay
FHS cell line (ATCC) and murine bone marrow cells
(derived from Balb/c, 6–8 weeks old) were used in cyto-
toxicity assays. The isolation of bone marrow stem cells
was performed according to previously reported methods
[35]. The animal protocol was approved by the Institu-
tional Animal Care Utilization Committee. FKB toxicity to
bone marrow stem cells and small intestinal epithelial cells
was tested by the cell counting kit-8 (Kumamoto, Japan)
after being exposed to different concentrations of FKB
for 72 h and measured by microplate reader scanning at
450 nm as described elsewhere [36]. Also the 143B cells
were used as control. Colony formation by mice bone
marrow cells was used to investigate the possible inhibi-
tory effect of FKB on bone marrow cells. After the bone
marrow cells were isolated, the yield and viability of cells
was determined by Trypan blue exculsion and counted
on a hemocytometer. A total number of 2×104 cells
were mixed with FKB or Adriamycin at concentration of
8.8 nM/ml, 17.6 nM/ml and 26.4 nM/ml, respectively. The
mixture was cultured in 1 ml ColonyGel™ 1201 MouseBase Medium (Reachbio) using a 6-well plate under stan-
dard culture conditions for 2 weeks. The number of co-
lonies was determined with an inverted phase-contrast
microscope at ×40 magnification. A group of >10 cells was
counted as a colony.
Statistical analysis
The data are presented as means ± standard errors (SE).
The level of significance was set at a P < 0.05. Comparison
of the differences between treated and control groups were
performed using the student’s t-test. All statistical tests
were two-sided. R2 value of correlation was determined for
MMP activity correlations to the FKB concentration using
Excel mac 2011.
Additional file
Additional file 1: FKB induces apoptosis and activates caspase 3/7, 8,
and 9 in 143B cells (*p<0.05).
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